Seroprotection and meningitis C: Meningococcal C booster not recommended by evidence

BMJ

Volumn 337, Issue 7666, 2008, Pages 367-

  Thomas, H Lucy ^a   Andrews, Nick ^a   Trotter, Caroline ^a   Ramsay, Mary ^a   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS GROUP C GLYCOCONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

DRUG EFFICACY; HERD IMMUNITY; HUMAN; LETTER; MATHEMATICAL MODEL; MENINGOCOCCOSIS; NASOPHARYNX; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 50049102973     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, Moore CE, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the UK: observational study. BMJ 2008; 36:1487-91. (28 June.)
2. Maiden MCJ, Ibarez-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke C, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43
3. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326:365-6.
4. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7.
5. Trotter CL, Edmunds WJ, Ramsay ME and Miller E. Modelling future changes to the meningococcal serogroup C conjugate (MCC) vaccine programme in England and Wales. Hum Vaccines 2006:2:68-73.